TY - CHAP
T1 - Behavioral pharmacology of drugs acting at mu opioid receptors
AU - Gerak, Lisa R.
AU - Maguire, David R.
AU - France, Charles P.
N1 - Funding Information:
This work was supported by the National Institutes of Health, National Institute on Drug Abuse [Grants R01 DA005018, R01 DA048417, and R21 DA 046805], and the Welch Foundation [Grant AQ-0039]. The authors have no conflict of interest. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the National Institute on Drug Abuse.
Publisher Copyright:
© Springer Nature Switzerland AG 2019.
PY - 2020
Y1 - 2020
N2 - Despite the therapeutic utility of opioids for relieving pain, other behavioral effects, including their potential for abuse and overdose, can be quite detrimental to individuals as well as society and have contributed to the ongoing opioid crisis. The dramatic escalation in overdose deaths over the last 15 years was initially driven by abuse of prescription opioids, although abuse of heroin, fentanyl, and fentanyl analogs has been increasing, largely due to increased availability and lower cost compared with prescription opioids. All of these opioids share pharmacological properties, acting as agonists at mu opioid receptors, and produce similar behavioral effects, including abuse-related, pain-relieving, dependence-producing, and respiratory-depressant effects. Despite their similarities, opioids are not pharmacologically identical. In fact, drugs that act at mu opioid receptors, including abused opioids, can vary on a number of dimensions, including pharmacological efficacy, drug-receptor interactions, receptor selectivity, and pharmacokinetics. Overall, these differences impact behavioral effects of drugs acting at mu opioid receptors, and this chapter describes variations in those behavioral effects and how these differences continue to provide new strategies that can be developed to address the ongoing opioid epidemic.
AB - Despite the therapeutic utility of opioids for relieving pain, other behavioral effects, including their potential for abuse and overdose, can be quite detrimental to individuals as well as society and have contributed to the ongoing opioid crisis. The dramatic escalation in overdose deaths over the last 15 years was initially driven by abuse of prescription opioids, although abuse of heroin, fentanyl, and fentanyl analogs has been increasing, largely due to increased availability and lower cost compared with prescription opioids. All of these opioids share pharmacological properties, acting as agonists at mu opioid receptors, and produce similar behavioral effects, including abuse-related, pain-relieving, dependence-producing, and respiratory-depressant effects. Despite their similarities, opioids are not pharmacologically identical. In fact, drugs that act at mu opioid receptors, including abused opioids, can vary on a number of dimensions, including pharmacological efficacy, drug-receptor interactions, receptor selectivity, and pharmacokinetics. Overall, these differences impact behavioral effects of drugs acting at mu opioid receptors, and this chapter describes variations in those behavioral effects and how these differences continue to provide new strategies that can be developed to address the ongoing opioid epidemic.
KW - Behavioral pharmacology
KW - Drug-receptor interactions
KW - Efficacy
KW - Mu opioid receptors
KW - Opioid abuse
KW - Treatments
UR - http://www.scopus.com/inward/record.url?scp=85085229685&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085229685&partnerID=8YFLogxK
U2 - 10.1007/164_2019_265
DO - 10.1007/164_2019_265
M3 - Chapter
C2 - 31451969
AN - SCOPUS:85085229685
T3 - Handbook of Experimental Pharmacology
SP - 127
EP - 145
BT - Handbook of Experimental Pharmacology
PB - Springer
ER -